
UCSF DERMATOLOGY GRAND ROUNDS – APRIL 2024

Lecture: Zoom (8:10 am – 9:10 am) or Herbst Hall, 1600 Divisadero Street, 2nd Floor

Patient Presentations and Discussion: Zoom (9:10 am – 10:15 am)

Moderator: Anna Haemel, MD

Information: Laura.Harrison@ucsf.edu

April 3, 2024

Grand Rounds and Patient Viewing

In-Person Only, Herbst Hall, 1600 Divisadero Street 2nd Floor

Opportunities and Challenges in the Treatment of Human Papillomavirus Infection

Carrie Kovarik, MD, Professor, Dermatology, Dermatopathology, Infectious Diseases, University of Pennsylvania, Philadelphia, PA

Objectives:

1. Determine treatment options for challenging cases of Human Papillomavirus (HPV) on the skin and mucous membranes
 2. Understand when to consider malignancy in cases of HPV and how to work with other specialties to optimize treatment
-

April 10, 2024

Grand Rounds and Patient Viewing

Zoom

Resident Expert Talks

Photodynamic therapy: shining a light on efficacy and recent advancements in PDT

Cory Kosche, MD, Chief, PGY-4 Resident, Department of Dermatology, UCSF

Objectives:

1. Understand the fundamental principles of photodynamic therapy, including the mechanisms of photosensitization and light activation
 2. Identify and differentiate between various sensitizing medications and light sources utilized in photodynamic therapy
 3. Review expanded indications for photodynamic therapy beyond traditional dermatological applications including neoplastic, inflammatory, and cosmetic conditions
-

Surgical Perspectives on Hidradenitis Suppurativa: Evaluating Procedural Indications, Techniques, and Outcomes

Fiatsogbe Dzuali, MD, PGY-4 Resident, Department of Dermatology, UCSF

Objectives:

1. Understanding the Indications for Surgical Intervention in Hidradenitis Suppurativa: Gain insight into the clinical criteria and patient factors that necessitate surgical management, including the stages and lesions of HS that benefit most from surgical intervention, and the decision-making approach to referrals for procedural management.
 2. Exploring Procedural Techniques and Their Outcomes in Hidradenitis Suppurativa: Become familiar with various procedural management options for HS. Discuss the success rates, patient experiences, and potential complications associated with these methods to better inform patient referrals and manage expectations.
-

April 17, 2024

Grand Rounds and Patient Viewing

In-Person Only, Herbst Hall, 1600 Divisadero Street 2nd Floor

Reed Lecture

Autoinflammatory Skin Diseases

Edward W. Cowen, MD, MHSc, Chief, Dermatology Consultation Service, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health

Objectives:

1. Understand the common inflammatory pathways that underlie monogenic autoinflammatory diseases.
 2. Recognize the cutaneous signs and internal organ systems affected by autoinflammatory diseases.
 3. Develop a mechanism-based approach to management of autoinflammatory diseases.
-

April 24, 2024

Grand Rounds and Patient Viewing

In-Person Only, Herbst Hall, 1600 Divisadero Street 2nd Floor

Placebo therapy in dermatology: Ethical and effective

M. Ramam, MD, Professor of Dermatology & Venereology, All India Institute of Medical Sciences, New Delhi

Objectives:

1. Recognise the value of placebo therapy in an empathetic and supportive clinical setting
 2. Learn about mechanisms underlying the placebo effect
 3. Learn about expert consensus guidelines for the ethical use of placebo therapy
-

(Course Number MGR 23062)

In support of improving patient care, UCSF Office of CME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

University of California, San Francisco, designates this live activity for a maximum of 40AMA PRA Category 1 credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. No more than 2 credits may be claimed for each 2-hour session.

Speaker Disclosures:

Carrie Kovarik, MD, Fiatsogbe Dzuali, MD, Cory Kosche, MD, Edward Cowen, MD, MHSc have all stated that they have no financial relationships to disclose. M. Ramam, MD has disclosed that he is a Royalties/Holder of Intellectual Property Rights with Pfizer.

Moderator Disclosures:

Anna Haemel, MD has disclosed that she is an advisor or reviewer for CSL Behring and a consultant for Guidepoint LLC.

Planner Disclosures:

Ilona Frieden, MD has disclosed that she is a consultant for Venthera Bridgebio, Data Safety Monitoring Advisory Board for Pfizer, and Data Reviewer on the NCT02913612 Pediatric Trials Network-NIH Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01).

Kelly Cordoro, MD, Hunter Shain, PhD and Amanda Twigg, MD have stated they have no relationships to disclose.